From BioHealth Investor
Biotechnology
POLYDEX PHARM LTD [POLXF] +28.84%
CERAGENIX PHARMACUTL [CGXP.OB] +9.00%
PANACOS PHARMA INC [PANC] +7.76%
PIPEX PHARMACEUTICAL [PPXP.OB] +4.62%
MICROMET INC [MITI] +4.59%
Diagnostic Substances
RG GLBL LIFESTYLS [RGBL.OB] +8.00%
HEALTHCARE TECH LTD [HCTL] +4.32%
INTERLEUKIN GENETICS [ILI] +2.53%
THRESHOLD PHARMACEUT [THLD] +1.84%
EZ EM INC [EZEM] +1.50%
Drug Delivery
GENEREX BIOTECH CORP [GNBT] +1.79%
PENWEST PHARM CO [PPCO] +0.87%
SKYEPHARMA PLC [SKYE] +0.73%
INSITE VISION INC [ISV] +0.69%
Drug Manufacturers
TAPESTRY PHARMA INC [TPPH] +10.76%
JAVELIN PHARMACEUTIC [JAV] +7.49%
CELL THERAPEUTICS [CTIC] +6.58%
PROTALEX INC [PRTX.OB] +5.26%
AMARIN CORP PLC AD [AMRN] +5.22%
Medical Appliances & Equipment
HANSEN MEDICAL, INC. [HNSN] +4.81%
CHAD THERAPEUTICS [CTU] +3.82%
DYNATRONICS CP [DYNT] +3.37%
NXSTAGE MEDICAL, INC [NXTM] +2.63%
SYMMETRY MEDICAL INC [SMA] +2.32%
Medical Instruments & Supplies
VYTERIS HOLDINGS NV [VYHN.OB] +11.61%
PRO-DEX INC NEW [PDEX] +5.26%
STEN CORPORATION [STEN] +5.00%
BIOLASE TECH INCS3 [BLTI] +4.99%
BIOFORCE NANOSCIENCE [BFNH.OB] +3.70%
Medical Laboratories & Research
LABORATORY CORP NEW [LH] +1.08%
NATL DENTEX CP [NADX] +0.36%
http://www.biohealthinvestor.com/
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
